

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/777,008	02/11/2004	Emil Martin	2105-01001	3412
23505	7590 08/03/2006		EXAMINER	
CONLEY ROSE, P.C. P. O. BOX 3267 HOUSTON, TX 77253-3267			GITOMER, RALPH J	
			ART UNIT	PAPER NUMBER
			1655	
		DATE MAILED: 08/03/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summany	10/777,008	MARTIN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Ralph Gitomer	1655				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D.  Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 06 Ju	une 2006					
·— · · <u>——</u>	action is non-final.					
.—						
• • • • • • • • • • • • • • • • • • • •	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
closed in additional with the practice under a	Expans quayio, 1000 C.D. 11, 10					
Disposition of Claims						
4)⊠ Claim(s) <u>1-6 and 18-21</u> is/are pending in the a	4)⊠ Claim(s) <u>1-6 and 18-21</u> is/are pending in the application.					
4a) Of the above claim(s) 3-6 is/are withdrawn	4a) Of the above claim(s) <u>3-6</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1,2 and 18-21</u> is/are rejected.						
7) ☐ Claim(s) is/are objected to.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
	priority under 25 U.S.C. & 110(a)	(d) or (f)				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)	🗖	(0.70)				
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
2) ☐ Notice of Dialisperson's Fatein Diawing Neview (FTO-945)  3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  5) ☐ Notice of Informal Patent Application (PTO-152)						
Paper No(s)/Mail Date 6) Other:						

Application/Control Number: 10/777,008

Art Unit: 1655

Applicant's election with traverse of Group I, claims 1, in the reply filed on 6/6/06 is acknowledged. The traversal is on the ground(s) that Groups I and II should be combined because as amended modulating encompasses activating or inhibiting enzyme activity. Claims 1, 2, 18, 19 and 21 are considered here, claims 3-6 are withdrawn from consideration.

The requirement is still deemed proper and is therefore made FINAL.

Upon resolution of the following issues, further searching and/or consideration may be required.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 2, 18-21 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Each of the following applies in all occurrences.

Claim 1 is directed to screening a substance but lacks any such step. Claim 1(b) is incomplete as to how cGMP would be formed because there is no reacting step. In claim 1(f) substances have activities, not abilities. Standard method steps may include obtaining, reacting, determining, and correlating. Claim 2 is not understood in context because it has no outcome from claim 1 and what the comparison result would be to indicate the substance enhances cGMP production is not recited. In claim 18 and all occurrences. "the outcome" lacks antecedent basis. Further, claim 18 is not

Application/Control Number: 10/777,008

Art Unit: 1655

understood. In claim 19 reference to step (f) is unclear as to what claim is intended.

Claims 18-20 refer to step (f) but not what the value would need to be.

The abstract of the disclosure is objected to because it contains legal terminology. Correction is required. See MPEP § 608.01(b).

The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ralph Gitomer whose telephone number is (571) 272-0916. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571) 272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/777,008 Page 4

Art Unit: 1655

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Roctono

Ralph Gitomer Primary Examiner Art Unit 1655

RALPH GITOMER
PRIMARY EXAMINER
GROUP 1200